SCHEDULE: Actyus Private Equity Discloses 1.64% Stake in Elicio
Beneficial Ownership Report (Amendment)
Actyus Private Equity SGIIC, S.A. has filed an amended Schedule 13G, disclosing a 1.64% beneficial ownership stake in Elicio Therapeutics, Inc.
Summary
- Actyus Private Equity SGIIC, S.A., a Spanish investment management company, reported beneficial ownership of 268,564 shares of Elicio Therapeutics, Inc. Common Stock.
- This ownership represents 1.64% of Elicio Therapeutics' outstanding Common Stock.
- The shares are held on behalf of NAVIS VB FUND I, a fund organized under the laws of Spain, with Actyus acting as the management company.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a previous filing and an update to the ownership information.
- The percentage of class is calculated based on 16,338,284 shares of Common Stock outstanding as of August 5, 2025, as reported in Elicio's Form 10Q filed on August 7, 2025.
- Actyus Private Equity SGIIC, S.A. holds sole voting power and sole dispositive power over all 268,564 shares.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership, indicating a passive investment. It does not contain information that would significantly alter the perceived sentiment towards the company or the investor.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- The filing includes certifications from Yasmina Armengol Hierro, Financial Director, and Alessia Carretie Colombo, Business Development Director, of Actyus Private Equity SGIIC, S.A., affirming the accuracy of the statement and that the securities were not acquired for the purpose of changing or influencing control of the issuer.
Industry Context
Schedule 13G filings are standard disclosures required by the SEC when an investor or group acquires beneficial ownership of more than 5% of a class of a company's voting equity securities, or in certain cases, when an institutional investor's ownership falls below or changes significantly from a previous filing. This filing indicates a passive investment by Actyus Private Equity in Elicio Therapeutics, a biotechnology company, without intent to influence control, which is typical for institutional investors holding smaller stakes.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Provides transparency to shareholders and the market regarding the ownership structure of Elicio Therapeutics, Inc.
- Confirms a passive investment stance by Actyus Private Equity SGIIC, S.A., indicating no immediate intent to influence management or control.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-08-05 | Date as of which 16,338,284 shares of Common Stock were outstanding for Elicio Therapeutics, Inc. |
| 2025-08-07 | Date Elicio Therapeutics, Inc. filed its Registration Statement on Form 10Q with the SEC, reporting outstanding shares. |
| 2025-09-30 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-10-07 | Date of signature for the Schedule 13G filing by Actyus Private Equity SGIIC, S.A. |
Keywords
Elicio Therapeutics, Actyus Private Equity, Beneficial Ownership, SEC Filing, Common Stock, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.